IASLC Targeted Therapies of Lung Cancer 2023 Conference Coverage


 

Appropriateness of Biomarker Selection for Durvalumab Consolidation Therapeutic Decision-Making in Stage III NSCLC

210 views
March 20, 2023
Comments 0
Login to view comments. Click here to Login